ABSTRACT
Arnebiae Radix is used widely in TCM external treatment. It has obvious curative effect on skin diseases， wound infection and local inflammation， and is used to treat water and fire burns， skin ulcers， eczema， psoriasis， vitiligo and atopic dermatitis， etc. The clinical and commercial preparations mainly include ointment， liniment and suppository. Modern research has proved that microcapsules， nano-micelles， nanofiber membranes， nanogels and other novel nanoformulations can significantly improve the stability of drug-effective substances， improve local drug concentration and targeting， and perform sound drug release properties in vitro. This paper reviews the variety and application of Arnebiae Radix traditional preparations for external use and the research progress of novel nanoformulations of Arnebiae Radix， from which we prospect to provide some valuable references for the future application and development of Arnebiae Radix external preparations.
ABSTRACT
The new external preparations of tr aditional Chinese medicine （TCM）mainly include transdermal drug delivery preparation and transmucosal drug delivery system. With the development of modern science and technology ，new external preparations of TCM are widely used in internal medicine ，gynecology，pediatrics and other diseases. In order to provide reference for dosage form development of TCM and safe use of drug in clinic ，this paper reviews the research progress of new external preparation technology for TCM （skin penetration method ，carrier encapsulation technology ，etc.），new external dosage forms of TCM（microneedles，gels，patches，film sprays ，suppositories，film agents ，in situ gels ，etc.）. In the future ，the research of new external preparations of TCM should conduct under the guidance of TCM theory ，and pay attention to the new drug delivery system of previous drugs and the development of TCM components of “drug-adjuvant integration ”，strengthen the research on new external preparations of TCM compounds ，and establish an evaluation system in line with the overall characteristics of TCM so as to promote the sustainable development of new external preparations of TCM.
ABSTRACT
Objective To investigate the efficacy and safety of Qingpeng ointment treating adult chronic eczema.Methods In May 2018,cases of chronic eczema were searched in databases of Chongqing Weipu (2000-2017),China Knowledge Resource Integrated Database (2000-2017) and Wanfang (2000-2017) through Nanjing Medical University Library website in the Department of Dermatology,Suzhou Science and Technology Town Hospital.RevMan5.3 software provided by Cochrane collaboration was used for Meta-analysis.To ensure data reliability,only the documents from Grade three hospitals were included.The experimental group was treated with Qingpeng ointment,while the control group was treated with weakly potent glucocorticosteroid,such as glucocorticoid cream,or moderately potent glucocorticosteroid,such as hydrocortisone butyrate cream,fluticasone propionate,halometasone and triamcinolone urea cream.Results Totally,7 randomized controlled trials,among which 258 patients in the trial group and 242 patients in the control group were included.The odds ratio (OR) values of Qingpeng ointment relative to glucocorticoid group at 2 and 4 weeks were 0.95 (0.52,1.72) and 0.80 (0.29,2.25) respectively,showing no significant difference (P =0.54and P =0.60,respectively,95 ％ Confidence Interval).Compared with hydrocortisone butyrate treating group,the OR value was 0.75 (0.31,1.82).And compared with moderately potent mometasone furoate,there was no significant difference in two-week and four-week treatment groups 0.99 (0.50,1.95),1.10 (0.18,6.53) (P=0.38 and P=0.36).No obvious adverse reactions were found in Qingpeng ointment treated group.Conclusions Qingpeng ointment is safe and effective in treating chronic eczema.There is no significant difference between Qingpeng ointment treating group and glucocorticosteroid treating group.Qingpeng ointment can be used as a safe external medicine for the treatment of chronic eczema.
ABSTRACT
Objective To evaluate the curative effect of Keli-Paoxi power for the treatment of acute paronychia. Methods A total of 144 patients with acute paronychia were randomly divided into a Keli-Paoxi power group, a mupirocin ointment group and an ethanol soaking group, 48 in each group. All patients were treated for 3 weeks and followed-up for 2 months. The time to regression of redness and swelling in the nail groove was recorded. The Visual Analogue Scale (VAS) was used to assess tenderness. The curative effects were evaluated, and recurrence of paronychia was recorded. Results The time to regression of redness and swelling in the nail groove in the Keli-Paoxi power group (2.2 ± 0.6 d) was significantly shorter than that in the mupirocin ointment group (8.1 ± 1.7 d) or ethanol soaking group (7.9 ± 1.2 d; F=344.597, P<0.01). The VAS Scores in the Keli-Paoxi power group (1.2 ± 0.2) was significantly lower than that in the mupirocin ointment group (3.2 ± 0.3) or ethanol soaking group (3.1 ± 0.3; F=831.273, P<0.01). The total effective rate in the Keli-Paoxi power group (100.0%, 48/48) was significantly higher than that in the mupirocin ointment group (83.3%, 40/48) or ethanol soaking group (81.3%, 39/48; χ2=9.700, P=0.008). The recurrence rate of paronychia in the Keli-Paoxi power group (2.1%, 1/48) was significantly lower than that in the mupirocin ointment group (16.7%, 8/48) or ethanol soaking group (14.6%, 7/48; χ2=6.000, P=0.049) at 2 months follow-up. Conclusions Keli-Paoxi power can alleviate tenderness, shorten the time to regression of redness and swelling in the nail groove, decraese recurrence in patients with acute paronychia. The curative effect of Keli-Paoxi power is superior to mupirocin ointment and ethanol soaking in the treatment of acute paronychia.